CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.


Player Avatar DarthMaul09 (29.79) Submitted: 11/4/2011 11:39:56 PM : Underperform Start Price: $9.11 DNDNQ Score: +9.14

Medication formularies are more likely to contract as profit margins for insurance companies fall. Independent of how potentially beneficial a new drug may initially appear, there will be a slow acceptance of any treatment that cannot compete on the basis of cost. In this environment their best hope is that their stock price continues to fall to a level where a larger pharm company buys them out for their patents. This may help some of the people that work for the company but it won't help the investors.

Featured Broker Partners